

1 **Circulating microRNAs are related to cognitive domains in the general**  
2 **population**

3  
4 **Authors**

5 Konstantinos Melas<sup>a</sup>, Valentina Talevi<sup>a</sup>, Rika Etteldorf<sup>a</sup>, Santiago Estrada<sup>a,b</sup>, Dennis M.  
6 Krüger<sup>c</sup>, Tonatiuh Pena<sup>c, d</sup>, N. Ahmad Aziz<sup>a,e</sup>, André Fischer<sup>c,f,g</sup>, Monique M.B. Breteler<sup>a,h</sup>

7 **Affiliations**

8 <sup>a</sup>Population Health Sciences, German Centre for Neurodegenerative Diseases (DZNE),  
9 Venusberg-Campus 1/99, 53127 Bonn, Germany

10 <sup>b</sup>AI in Medical Imaging, German Centre for Neurodegenerative Diseases (DZNE),  
11 Venusberg-Campus 1/99, 53127 Bonn, Germany

12 <sup>c</sup>Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German  
13 Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075 Göttingen,  
14 Germany

15 <sup>d</sup>Bioinformatics Unit, German Centre for Neurodegenerative Diseases (DZNE), Von-  
16 Siebold-Str. 3a, 37075 Göttingen, Germany

17 <sup>e</sup>Department of Neurology, Faculty of Medicine, University of Bonn, Venusberg-Campus  
18 1/80, 53127 Bonn, Germany

19 <sup>f</sup>Department for Psychiatry and Psychotherapy, University Medical Center Göttingen, Von-  
20 Siebold-Str. 5, 37075 Göttingen, Germany

21 <sup>g</sup>Cluster of Excellence MBExC, University of Göttingen & University Medical Center  
22 Goettingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany

23 <sup>h</sup>Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Faculty of  
24 Medicine, University of Bonn, Venusberg-Campus 1/11, 53127 Bonn, Germany

25 **Corresponding Author**

26 Monique M.B. Breteler, MD PhD

27 Director of Population Health Sciences

28 German Center for Neurodegenerative Diseases (DZNE)

29 Venusberg-Campus 1, Building 99

30 53127 Bonn

31 Germany

32 Tel +49 228 43302-929

33 Email: monique.breteler@dzne.de

34 ORCID: 0000-0002-0626-9305

35

36 Total word count (title page, abstract, text, references, tables, and figure legends): 10792

37 Word count for abstract: 150

38 Number of tables: 1

39 Number of figures: 6

40

41 **Declarations of interest:** none

42

43 **Contact data of authors**

44 *Konstantinos Melas*

45 E-mail: Konstantinos.melas@dzne.de

46 ORCID: 0009-0000-5206-5322

47

48 *Valentina Talevi*

49 E-Mail: Valentina.Talevi@dzne.de

50 ORCID: 0000-0003-4418-7439

51

52 *Rika Etteldorf*

53 E-mail: Rika.Etteldorf@dzne.de

54 ORCID: 0009-0008-6317-7934

55

56 *Santiago Estrada*

57 E-Mail: Santiago.Estrada@dzne.de

58 ORCID: 0000-0003-0339-8870

59

60 *Dennis M. Krüger*

61 E-mail: Dennis.Krueger@dzne.de

62 ORCID: 0000-0003-1950-9547

63

64 *Tonatiuh Pena*

65 E-Mail: [Tonatiuh.Pena@dzne.de](mailto:Tonatiuh.Pena@dzne.de)

66 ORCID: 0000-0002-9329-8912

67

68 *N. Ahmad Aziz*

69 E-Mail: [Ahmad.Aziz@dzne.de](mailto:Ahmad.Aziz@dzne.de)

70 ORCID: 0000-0001-6184-458X

71

72 *Andre Fischer*

73 Email: [Andre.Fischer@dzne.de](mailto:Andre.Fischer@dzne.de)

74 ORCID: 0000-0001-8546-1161

75

76 **ABSTRACT**

77 **INTRODUCTION:** Circulating microRNAs have been suggested as candidates for detecting  
78 and preventing subclinical cognitive dysfunction. However, replication of previous findings  
79 and identification of novel microRNAs associated with cognitive domains, including their  
80 relation to brain structure and the pathways they regulate, are still lacking.

81 **METHODS:** We examined circulating microRNAs and microRNA *co-expression* clusters in  
82 relation to cognitive domains, structural MRI measures, and target gene expression in 2869  
83 participants of a population-based cohort.

84 **RESULTS:** Five previously identified and 10 novel microRNAs were associated with  
85 cognitive domains. Importantly, seven of these microRNAs were also associated with cortical  
86 thickness and two with hippocampal volume. Functional genomics analysis showed that the  
87 identified microRNAs regulated genes in pathways like neurogenesis, axon guidance, and  
88 synapse assembly.

89 **DISCUSSION:** We identified microRNAs associated with cognitive domains, brain regions,  
90 and neuronal processes affected by aging and neurodegeneration, making them promising  
91 candidate blood-based biomarkers or therapeutic targets of subclinical cognitive dysfunction.

92

93 **KEYWORDS**

94 microRNA; cognition; population-based; biomarker; cortical thickness; miR-215-5p; miR-  
95 192-5p; miR-134-5p; miR-92b-3p; miR-10401-3p; miR-4677-5p; miR-4732-3p; miR-92a-3p;  
96 miR-128-3p; miR-125b-5p

97

## 98 **1 BACKGROUND**

99 Mitigating the impact of cognitive aging remains one of the biggest challenges of the 21<sup>st</sup>  
100 century [1]. Early detection of subclinical cognitive dysfunction is necessary to enable  
101 interventions at the earliest stages of its pathophysiology [2]. Currently, tailored  
102 neuropsychological test batteries are the gold standard for detecting cognitive dysfunction.  
103 However, such batteries can be time-consuming, require experienced examiners, and are  
104 dependent on individual traits such as language and cultural background. Moreover, their  
105 sensitivity in the very early stages of cognitive dysfunction, and in highly educated persons,  
106 is limited [3]. The identification of blood-based molecular biomarkers of subclinical  
107 cognitive dysfunction could facilitate earlier and more reliable detection of individuals at risk  
108 of accelerated cognitive aging or neurodegeneration [4]. Additionally, such biomarkers might  
109 point to specific pathophysiologic processes involved in cognitive aging, and thus help the  
110 development of targeted interventions.

111 Various blood-based biomarkers have been investigated for the early detection of cognitive  
112 dysfunction, including neurodegenerative [4], lipidomic, inflammatory [5] and proteomic [6]  
113 markers. A highly promising line of research focuses on microRNAs [7,8]. These small,  
114 endogenous, non-coding RNAs bind to target genes, mainly through base pairing, leading to  
115 degradation of these genes or inhibition of their translation. A single microRNA can have  
116 several physiological effects through the regulation of multiple genes [9]. Additionally,  
117 microRNAs are highly expressed in the brain, where they regulate functions like synaptic  
118 plasticity and memory. Brain-enriched microRNAs can cross the blood-brain barrier and  
119 enter the peripheral circulation, where they remain stable for extended periods [8]. Thus,  
120 microRNAs have been investigated for the diagnosis and treatment of neurodegenerative  
121 diseases [10]. For example, circulating microRNA-based panels were shown to have high  
122 accuracy in diagnosing Alzheimer's Disease (AD), and one such diagnostic panel has entered

123 phase I of clinical development [11]. Conversely, microRNA-based therapeutics have been  
124 hindered by the incomplete characterization of the functions of tested microRNAs, which can  
125 lead to unforeseen side effects [11].

126 To assess whether circulating microRNAs can be employed for early detection or prevention  
127 of cognitive dysfunction, their association with cognition must be investigated in non-  
128 demented individuals, and their functions must be better understood. In the past, a few  
129 population-based studies identified microRNA signatures associated with general cognitive  
130 function and decline [12,13], verbal memory changes longitudinally [14], or multiple  
131 cognitive domains cross-sectionally [15]. A recent study identified a three-microRNA  
132 signature related to cognitive function and decline, by combining population-level and animal  
133 model data [16]. However, most of these studies had relatively small samples, potentially  
134 limiting their capability to detect microRNAs with weaker effect sizes. Specifically, the  
135 largest study included 1615 participants [12], while the rest had sample sizes ranging from  
136 132 [16] to 830 [15] participants. Moreover, the only study that examined more than one  
137 cognitive domain evaluated only a small number (n=38) of microRNAs previously linked to  
138 AD [15]. Thus, there is a need for studies combining larger sample sizes, multiple cognitive  
139 domains, and the untargeted evaluation of many microRNA transcripts. In addition, it is  
140 worth noting that only five microRNAs (miR-4732-3p, miR-363-3p, miR-181a-5p, miR-  
141 146a-5p and let-7c-5p) overlapped among at least two of these studies. This reflects a greater  
142 problem in microRNA research. The large heterogeneity in microRNA sampling and  
143 quantification methods often leads to inconsistent results among studies, which highlights the  
144 need for replication [17]. Lastly, none of these studies examined the association of cognition-  
145 related microRNAs with brain structure or gene expression. This could provide information  
146 on key microRNA-regulated biological pathways, enabling their use as therapeutic targets  
147 against cognitive decline.

148 Here, we aimed to first identify blood-circulating microRNAs associated with the major  
149 domains of cognitive function, by replicating the results of previous studies and identifying  
150 novel associations in a population-based cohort consisting of 2869 individuals. Next, we  
151 determined which of the identified cognition-related microRNAs were associated with brain  
152 structure. Lastly, leveraging gene expression data through a functional genomics approach,  
153 we elucidated the molecular pathways through which the identified microRNAs could affect  
154 cognitive function and brain structure.



## 155 **2 METHODS**

### 156 **2.1 Study Design**

157 Our analysis was based on cross-sectional baseline data from the Rhineland Study, an  
158 ongoing prospective, population-based cohort study in Bonn, Germany. All residents of two  
159 geographically defined areas in Bonn, aged 30 years or older, were invited to participate in  
160 the study. The only exclusion criterion was an insufficient command of the German language  
161 to provide informed consent. One of the main goals of the Rhineland Study is to investigate  
162 biomarkers and determinants of aging and age-related diseases in the general population,  
163 following a deep-phenotyping approach. Each participant undergoes a comprehensive 7-hour  
164 examination protocol, which includes detailed questionnaires, brain imaging,  
165 neuropsychological examinations, and blood sample analyses.

### 166 **2.2 Standard protocol approvals, registrations, and participant consent**

167 Approval to undertake the study was obtained from the ethics committee of the University of  
168 Bonn, Medical Faculty. The study is carried out in accordance with the recommendations of  
169 the International Conference on Harmonization Good Clinical Practice standards. We  
170 obtained written informed consent from all participants in accordance with the Declaration of  
171 Helsinki.

### 172 **2.3 Study population**

173 Biomaterial was selected from the first 3000 participants of the Rhineland Study who  
174 provided blood samples for microRNA sequencing. MicroRNA expression data was missing  
175 due to technical issues (n=33) or exclusion during quality control (n=38). From the remaining  
176 2929, we excluded 60 participants because of missing cognition data (due to:

177 contraindications/exclusion criteria, n=7; participant refusal, n=3; technical issues, n=3;  
178 exclusion during quality control, n=9; a combination of the above, n=38), leaving 2869  
179 participants with both microRNA expression and cognitive performance data (“cognition  
180 dataset”). Brain imaging data were available for a subset of 2045 participants of the cognition  
181 dataset (brain imaging data missing due to: contraindications/exclusion criteria, n=452;  
182 participant refusal, n=330; other/ unknown reasons, n=42). Gene expression and blood cell  
183 count data were available for a subset of 2138 participants of the cognition dataset (gene  
184 expression data missing due to: technical issues, n=475; exclusion during quality control,  
185 n=129; blood cell count data missing due to: technical issues, n=126; unknown reasons, n=1).  
186 The overlap of the subset with complete MRI data and the subset with complete gene  
187 expression and blood cell count data consisted of 1534 participants.

## 188 **2.4 Blood sample acquisition and RNA isolation**

189 Blood samples were collected between 7:00 to 9:45 in the morning from an antecubital or  
190 dorsal hand vein. On some occasions, blood sample collection was performed on a different  
191 visit than the cognitive evaluation. The time difference between the two visits was usually  
192 less than one month. Whole blood samples for microRNA and gene expression (messenger  
193 RNA) sequencing were collected in PAXgene Blood RNA tubes (PreAnalytix/Qiagen) and  
194 stored at -80° Celsius. Before sequencing, PAXgene Blood RNA Tubes were thawed and  
195 incubated at room temperature to increase RNA yield. Total RNA was isolated according to  
196 manufacturer’s instructions using the PAXgene Blood miRNA Kit and following the  
197 automated purification protocol (PreAnalytix/Qiagen).

## 198 **2.5 MicroRNA and gene expression measurement**

199 We performed the microRNA sequencing on the Illumina HiSeq 2000 over 44 batches, and  
200 the RNA sequencing on the NovaSeq6000 platform over 28 batches. Detailed information on  
201 our microRNA and gene sequencing and analysis pipeline is provided in **Supplementary**  
202 **Methods 1**. MicroRNAs and genes with overall mean expression levels greater than 15 reads  
203 and expressed in at least 5% of the participants were included for further analysis, resulting in  
204 a total of 415 microRNAs and 11,325 genes. Raw counts were normalized and transformed  
205 using the *varianceStabilizingTransformation* function from *DESeq2* (v1.30.1), which  
206 includes a log<sub>2</sub> transformation [18]. Mean normalized counts of sequenced microRNAs  
207 ranged from 3.09 (for miR-4707-3p) to 21.34 (for miR-486-5p). As a last step, microRNA  
208 and gene expression data were adjusted for sequencing batch effects by creating a linear  
209 regression model, with microRNA normalized counts as the dependent variable and  
210 sequencing batch as the independent variable, and extracting the model residuals.

## 211 **2.6 Assessment of cognitive function**

212 The neuropsychological test battery of the Rhineland Study has been described in detail  
213 elsewhere [19]. Examined domains included working memory, episodic verbal memory,  
214 processing speed, executive function, and crystallized intelligence. Working memory was  
215 assessed with the orally performed Digit Span forward and backward task, and the touchpad-  
216 based Corsi block-tapping test, based on the Psychology Experiment Building Language  
217 battery [20]. Episodic verbal memory was evaluated with the Auditory Verbal Learning and  
218 Memory test with a list length of 15 words [21]. Assessment of processing speed was based  
219 on a numbers-only trail-making test (Trail-making test A), and prosaccade latency (time  
220 needed to initiate a saccade), derived from an eye movement test battery [22]. We examined  
221 executive function using the antisaccade error rate (percentage of trials in which the  
222 participant made a direction error) from the same battery, combined with a categorical word

223 fluency task (animals), and number-and-letters trail-making test (Trail making test B). Lastly,  
224 we measured crystallized intelligence with the 37-item Mehrfachwahl-Wortschatz-  
225 Intelligenztest [23]. Cognitive domain performance scores were created by averaging the z-  
226 scores of the tests contributing to each domain. The creation of these z-scores was based on  
227 data from the first 5000 participants of the Rhineland Study. Additionally, we averaged the z-  
228 scores for working memory, episodic verbal memory, processing speed, and executive  
229 function to create a global cognition composite score. All examinations were administered in  
230 the German language, following a standardized procedure by certified study technicians.

## 231 **2.7 Image acquisition and brain segmentation**

232 Participants underwent a one-hour examination protocol in 3T MRI scanners (Siemens  
233 Prisma Magnetom, Erlangen, Germany) equipped with a 64-channel head-neck coil [24].  
234 During the MRI section, a T1-weighted multi-echo magnetization prepared rapid gradient  
235 echo (MPRANGE) image was acquired [25]. T1-weighted images were processed with the  
236 standard Freesurfer (version 6.0) recon-all pipeline [26] to obtain the brain imaging  
237 phenotypes. For our analysis of MRI data, we evaluated regions relevant to cognitive aging  
238 and neurodegeneration, namely mean and regional cortical thickness, and hippocampal  
239 volume [27]. In addition, we evaluated total brain volume as a general indicator of brain  
240 health. Regional cortical thickness was evaluated for the 31 cortical Regions of Interest  
241 (ROIs) included in the Desikan–Killiany–Tourville (DKT) cortical atlas [28], and was  
242 separately assessed for the left and right hemispheres.

## 243 **2.8 Demographic and biochemical variables**

244 Participants' age and sex were included as demographic variables. Information on  
245 educational level, native language, and history of physician-diagnosed neuropsychiatric or

246 neurodegenerative disorders was based on self-reports. Educational level was determined  
247 using the International Standard Classification of Education 2011 and was coded as low  
248 (lower secondary education or below), middle (upper secondary education to undergraduate  
249 university level), and high (postgraduate university study). Native language was coded as  
250 German or other. Differential blood cell count measurements (erythrocytes, nucleated  
251 erythrocytes, leukocytes, and platelets) were performed at the Central Laboratory of the  
252 University Hospital in Bonn, using EDTA-whole blood samples on a hematological analyzer  
253 Sysmex XN9000.

## 254 **2.9 Statistical analysis**

255 Descriptive data were expressed as mean  $\pm$  standard deviation (SD) and counts with  
256 proportions for numerical and categorical variables. To compare cognitive scores among the  
257 main analytical sample and the subsamples used for brain imaging and gene expression  
258 analyses, we used Type III Analysis of Covariance adjusting for age and sex.

259 To examine the association of microRNA expression with cognitive scores, we followed two  
260 complementary methods. First, based on the *guilt-by-association* framework [29], we  
261 assumed that microRNAs that follow similar expression patterns act jointly to form  
262 biologically functional units. We utilized the Weighted Gene Co-expression Network  
263 Analysis (WGCNA) method [30], to create groups of similarly expressed microRNAs (*co-*  
264 *expression* analysis). This allowed us to account for the correlated structure of microRNA  
265 expression data, increasing our statistical power for detecting trait-related microRNAs.  
266 Second, we performed a *per microRNA* analysis, meaning that we directly examined the  
267 association of individual microRNAs with cognitive scores. This was done to account for  
268 single microRNAs that might be strongly related to cognitive outcomes, but only weakly co-  
269 expressed with other microRNAs, in which case the grouping method would be less effective.

270 2.9.1 Construction of weighted gene co-expression network

271 We clustered microRNAs in *co-expression* modules using the *WGCNA* R package (v.1.70-3)  
272 [30,31]. We chose a soft thresholding power of 7 based on scale-free topology, and we used  
273 the Hybrid Dynamic Tree Cut method to identify microRNA modules, with a minimum  
274 module size of 5. This resulted in 16 modules, which we refer to by randomly assigned colors  
275 (green, magenta, turquoise, black, pink, yellow, brown, red, blue, greenyellow, purple, cyan,  
276 salmon, lightcyan, midnightblue, tan). We then reduced the expression of all microRNAs in a  
277 module to a single value (module expression). Detailed information on the application of the  
278 WGCNA algorithm is provided in **Supplementary Methods 2**.

279 2.9.2 Association of module and microRNA expression with cognition

280 For the *co-expression* and *per microRNA* analyses we examined the association of module  
281 and microRNA expression with cognitive scores using multiple linear regression. Firstly, we  
282 converted all numeric variables to z-scores, to permit the comparability of all linear  
283 regression coefficients. Then, for each module, each microRNA, and each cognitive score we  
284 created a separate model including module or microRNA expression as the independent  
285 variable and cognitive score as the dependent variable while adjusting for age and sex (Model  
286 1: *cognitive score* ~ *microRNA or module expression* + *age* + *sex*). Additionally, we created a  
287 second model that included educational level and native language as covariates. For  
288 crystallized intelligence, however, we did not adjust for native language as German as a  
289 native language is a prerequisite for undertaking the test (Model 2: *cognitive score* ~  
290 *microRNA or module expression* + *age* + *sex* + *educational level* [+ *native language*]).  
291 Lastly, we performed a sensitivity analysis by excluding participants who reported a  
292 physician-diagnosed neuropsychiatric or neurodegenerative disorder (i.e., dementia,

293 Parkinson's disease, multiple sclerosis, stroke, schizophrenia), and re-ran Model 1 in the  
294 remaining sample.

#### 295 *2.9.2.1 Replication of microRNAs previously associated with cognition and AD or MCI*

296 The first part of our *per microRNA* analysis consisted of a replication analysis for *a priori*  
297 selected microRNAs. This included 46 microRNAs associated with cognition in previous  
298 similar studies [12–16], and 10 microRNAs consistently found to be differentially expressed  
299 in the blood of AD and Mild Cognitive Impairment (MCI) patients in a recent meta-analysis  
300 [17]. An overview of these studies can be found in **Supplementary Table S1**. As all of these  
301 studies only examined measures of fluid intelligence, for this analysis we only included  
302 cognitive scores that reflect fluid intelligence (i.e., global cognition, working memory,  
303 episodic verbal memory, processing speed, and executive function). One study examined the  
304 association of microRNA expression with cognition using linear regression, as well as  
305 comparing expression between two cognitive performance categories [15]. For this study, we  
306 included for replication microRNAs from the linear regression analysis, which presented  
307 greater similarity with our own method. *P* values for the replication analysis were not  
308 corrected for multiple testing.

#### 309 *2.9.2.2 Hypothesis-free analysis*

310 Beyond the replication analysis, the association of microRNAs with cognition was evaluated  
311 without *a priori* hypotheses and thus we corrected for multiple testing using the Benjamini-  
312 Hochberg false discovery rate (fdr) method. Specifically, *P* values were corrected for the  
313 number of modules (n=16) for the *co-expression* analysis, and for the number of microRNAs  
314 (n=415) for the *per microRNA* analysis.

315 After identifying modules significantly associated with cognitive scores in the *co-expression*  
316 *analysis*, we also identified hub microRNAs in these modules. These were defined as

317 microRNAs significantly associated with the same cognitive score as the module, and highly  
318 correlated with module expression (*high significance* and *high membership* microRNAs;  
319 **Supplementary Methods 2**). Here, *P* values were not corrected for multiple testing, as this  
320 was only done for the modules already significantly associated with cognitive scores. In all  
321 cases, the statistical significance level was set at 0.05 ( $\text{fdr} \leq .05$  or  $P \text{ value} \leq .05$ ).

### 322 2.9.3 Interaction and stratification based on age and sex

323 To examine whether age and sex modified the association of microRNAs with cognitive  
324 scores, we used additional linear models, including interaction terms between microRNA  
325 expression and age (Model 3: *cognitive score* ~ *microRNA expression* + *age* +  
326 *microRNA* × *age* + *sex*), or between microRNA expression and sex (Model 4: *cognitive score*  
327 ~ *microRNA expression* + *age* + *sex* + *microRNA* × *sex*). For microRNAs with a significant  
328 interaction term with either age or sex, we additionally performed a stratification analysis.  
329 This was done by splitting our main analytical sample based on median age in older ( $\geq 54$   
330 years) or younger ( $<54$  years) participants, and in men or women. We then ran Model 1 again  
331 in these age and sex strata.

### 332 2.9.4 Association of cognition-related microRNAs with brain MRI measures

333 MicroRNAs identified as significantly associated with cognition through the replication and  
334 hypothesis-free analyses were evaluated for their association with hippocampal volume,  
335 mean cortical thickness and total brain volume. MicroRNAs that were significantly  
336 associated with mean cortical thickness were further evaluated for their association with  
337 cortical ROI thickness. As for the association of microRNAs with cognitive scores, this was  
338 done by first converting numeric variables to z-scores and then employing multivariable  
339 linear regression. Brain *MRI* traits were included as the dependent variable and microRNA  
340 expression as the independent variable while adjusting for age and sex. When the dependent



341 variable was hippocampal or total brain volume, we additionally adjusted for estimated Total  
342 Intracranial Volume (eTIV), to account for differences in head size (Model: brain *MRI*  
343 *measure* ~ *microRNA or module expression* + *age* + *sex* [+ *eTIV*]). The results of this analysis  
344 were not corrected for multiple testing based on the *a priori* hypothesis that microRNAs  
345 associated with cognition would also be associated with brain structure.

## 346 **2.10 MicroRNA expression in tissues**

347 After identifying the microRNAs significantly associated with cognition, we assessed in  
348 which tissues they were most highly expressed. For this, we used miRNATissueAtlas2, an  
349 online resource that provides data on microRNA expression in 60 human tissues, acquired  
350 post-mortem from 6 donors [32]. Using this data, we converted microRNA expression across  
351 tissues to a z-score and we calculated the median of microRNA expression for each tissue  
352 across donors.

## 353 **2.11 Functional genomics analysis**

354 To determine genes that could be regulated by microRNA modules *in vivo*, we first obtained  
355 putative target genes for each microRNA using the *multimir* R package (v.1.12.0) [33].  
356 Subsequently, we examined the association between microRNA and target gene expression in  
357 our participants using linear regression, adjusting for age, sex, and blood cell counts (Model:  
358 *target gene expression* ~ *microRNA expression* + *age* + *sex* + *erythrocyte count* + *nucleated*  
359 *erythrocyte count* + *leukocyte count* + *platelet count*). We kept for further analysis genes  
360 whose expression was negatively associated with the expression of the targeting microRNA.  
361 These genes were then used for a pathway enrichment analysis, pooling target genes of  
362 microRNAs belonging to the same WGCNA module, and using the Gene Ontology:  
363 Biological Processes database and the “*clusterProfiler*” (v. 3.18.1) R Bioconductor package

364 [34]. Semantically similar terms were collapsed *post hoc* using the *rrvgo* (v. 1.2.0) R  
365 Bioconductor package [35], setting a small similarity threshold of 0.6. For detailed  
366 information on the identification of target genes and functional enrichment, refer to  
367 **Supplementary Methods 3**. We additionally examined the enrichment of target genes  
368 among genes identified in a published Genome-Wide Association Study (GWAS) of general  
369 cognitive function. This study identified 709 cognition-related genes, and gene expression  
370 data was available for 385 of those genes in our data [36]. The enrichment analysis was done  
371 by examining whether the target genes of each microRNA were overrepresented among the  
372 genes identified by the GWAS using a hypergeometric test (“*hyper*” R Bioconductor  
373 package, v.1.10.0). This analysis was performed for individual microRNAs and not per  
374 module, to identify the most relevant single microRNAs. The statistical significance level for  
375 enrichment analyses was set at .05 ( $fdr \leq .05$  or  $P$  value  $\leq .05$ ).

376 All analyses were performed using the R programming environment (v. 4.1.0).

## 377 **2.12 Data availability**

378 The data from the Rhineland Study are not publicly available due to data protection  
379 regulations. Access to data can be provided to scientists in accordance with the Rhineland  
380 Study’s Data Use and Access Policy. Requests for additional information or to access to the  
381 Rhineland Study’s datasets can be send to [RS-DUAC@dzne.de](mailto:RS-DUAC@dzne.de).

382

383

## 384 **3 RESULTS**

### 385 **3.1 Participant characteristics**

386 In our main analytical sample (cognition dataset, n=2869 participants), the mean age was  
387 55.01 years, (SD=14.13 years, range=30-95 years) and 56% of participants were women. The  
388 subset of participants with complete MRI data was slightly younger and had slightly higher  
389 cognitive domain scores (**Table 1**). However, when adjusted for age and sex, the cognitive  
390 domain scores did not significantly differ between the cognition dataset and its subsets (all *P*  
391 values > .1).

### 392 **3.2 Association of microRNAs and microRNA co-expression modules with cognition**

#### 393 *3.2.1 Replication of microRNAs previously associated with cognition, AD, or MCI*

394 Among the 46 microRNAs associated with cognition in previous population-based studies,  
395 miR-340-5p, miR-125b-5p, miR-4732-3p and miR-92a-3p were associated with at least one  
396 cognitive score in the same direction in our *per microRNA* analysis. Of note, miR-4732-3p  
397 had been found in two of the previous studies [12,13] and, among these 46 microRNAs, it  
398 had the strongest association with cognition in our data. Conversely, seven microRNAs were  
399 significantly associated with cognitive scores in the opposite direction in our data, compared  
400 to previous studies. Six of these microRNAs, miR-30e-3p, miR-342-5p, miR-574-5p, miR-  
401 320c, miR-215-5p, miR-320b, miR-122-5p, came from the same study by Comfort et al [13],  
402 which had included older (median age: 71 years) and only male participants. The seventh  
403 microRNA, miR-122-5p, had been identified in a study by Yaqub et al [12], which also  
404 included older participants (median age: 70.3 years) compared to our study (**Figures 1A &**  
405 **1B**). To examine whether these inconsistent findings were due to the age or sex differences in  
406 the examined populations, we included the six microRNAs from Comfort et al in a sex-

407 stratified analysis, and all seven microRNAs in an age-stratified analysis (shown in Section  
408 3.2.5).

409 Among the 10 microRNAs differentially expressed in AD and MCI [17], higher miR-128-3p  
410 expression had been previously found higher in MCI patients and was associated with worse  
411 global cognition, executive function and episodic verbal memory performance in our data  
412 (**Figure 1C**).

### 413 *3.2.2 Hypothesis-free co-expression analysis*

414 Beyond the replication of previous studies, we performed a hypothesis-free analysis to  
415 identify novel microRNA co-expression modules and hub microRNAs associated with  
416 cognition. Using WGCNA, we identified 16 microRNA co-expression modules with a size  
417 ranging from 5 to 129 microRNAs (**Supplementary Fig. S1**). Modules were named after  
418 randomly assigned colors Adjusting for age and sex, and after correction for multiple testing,  
419 higher expression of only one of these modules (lightcyan) was significantly associated with  
420 worse episodic verbal memory (standardized  $\beta$ : -0.048, 95% Confidence Interval [CI]: -0.078  
421 to -0.019, *fdr*-corrected *P* value: .021, adjusted  $R^2$ : 0.35). Additionally, we observed trends  
422 towards association of lower expression of another module (greenyellow) and higher  
423 expression of three modules (salmon, turquoise and pink) with better performance across  
424 most scores. However, none of these associations were significant after multiple testing  
425 correction (**Figure 2A**). When additionally adjusting for educational level and first language,  
426 increased expression of the greenyellow module became significantly associated with worse  
427 executive function (standardized  $\beta$ : -0.045, 95% CI: -0.075 to -0.016, *fdr*-corrected *P* value:  
428 .043, adjusted  $R^2$ : 0.36). With the same adjustment, higher expression of the lightcyan  
429 module remained significantly associated with worse episodic verbal memory, yet the  
430 association slightly weakened (standardized  $\beta$ : -0.041, 95% CI: -0.070 to -0.012, *fdr*-

431 corrected  $P$  value: .097, adjusted  $R^2$ : 0.39; **Figure 2B**). Based on these findings, we decided  
432 to retain the greenyellow and lightcyan modules for further analyses, as they demonstrated  
433 the strongest and most consistent associations with cognitive function.

434 We then identified hub microRNAs in these two modules, defined as microRNAs strongly  
435 correlated with module expression, while being significantly associated with the same  
436 cognitive domains as the modules (i.e., executive function for the greenyellow module and  
437 episodic verbal memory for the lightcyan module). In the model adjusted for age and sex,  
438 these conditions were fulfilled for four microRNAs from the greenyellow module, miR-134-  
439 5p, miR-409-3p, miR-370-3p and miR-493-3p, and for two microRNAs from the lightcyan  
440 module, miR-215-5p and miR-192-5p (**Figure 2C**).

### 441 *3.2.3 Hypothesis-free per microRNA analysis*

442 For the next step of the hypothesis-free analysis, we individually examined all microRNAs  
443 measured in our study ( $n=415$ ) in relation to cognitive function, regardless of co-expression  
444 module. Adjusting for age and sex, we identified four microRNAs, miR-92b-3p, miR-1976,  
445 miR-10401-3p and miR-4677-5p, which were significantly associated with executive  
446 function after multiple testing correction. The same microRNAs were significantly associated  
447 with global cognition, with the exception of miR-92b-3p, which was associated with global  
448 cognition at borderline significance (**Figure 2C**). Results changed only slightly when  
449 additionally adjusting for education and native language (**Supplementary Fig. S2**). Of note,  
450 miR-92b-3p is closely related to miR-92a-3p, which was identified in our replication analysis  
451 (Section 3.2.1). These two microRNAs belong to the same family (mir-25 family) and share  
452 highly similar mature sequences [37]. Despite that, their expression levels were only  
453 moderately correlated in our data (Pearson's correlation coefficient: 0.37, 95% CI: 0.34 to  
454 0.40)

455 Thus, combining the results from our literature replication, as well as our *co-expression* and  
456 *per microRNA* hypothesis-free analyses, we detected a signature of five previously identified  
457 (miR-340-5p, miR-125b-5p, mir-4732-3p, miR-92a-3p, miR-128-3p) and 10 novel  
458 microRNAs (miR-192-5p, miR-134-5p, miR-370-3p, miR-409-3p, miR-493-3p, miR-215-5p,  
459 miR-4677-5p, miR-10401-3p, miR-1976, miR-92b-3p) that were strongly related to  
460 cognition. Notably, while significant associations were primarily found with executive  
461 function or episodic verbal memory scores, these 15 microRNAs were nominally associated  
462 with most other cognitive scores as well (**Figure 3A**). Median values and distribution of the  
463 expression (normalized counts) of the 15 microRNAs can be found in **Supplementary Fig.**  
464 **S3**.

#### 465 *3.2.4 Neuropsychiatric and neurodegenerative disorder sensitivity analysis*

466 To ensure that our results were not confounded by dysregulation of microRNA expression  
467 due to neuropsychiatric or neurodegenerative disorders, we performed the same analysis after  
468 excluding participants with a self-reported physician diagnosis of dementia (n=3),  
469 Parkinson's disease (n=8), multiple sclerosis (n=13), stroke (n=48), and schizophrenia (n=2).  
470 This sensitivity analysis resulted in only slight differences in linear regression coefficients for  
471 the 16 co-expression modules and the 15 cognition-related microRNAs, without affecting  
472 statistical significance (**Supplementary Fig. S4**).

#### 473 *3.2.5 Age and sex as effect modifiers*

474 Next, we examined whether the association of the microRNAs with cognition was modified  
475 by age or sex. We detected significant positive interaction terms with age for the associations  
476 of miR-128-5p with episodic verbal memory and global cognition, miR-125b-5p with  
477 executive function and crystallized intelligence, and miR-92a-3p with working memory. Age-

478 stratified analysis confirmed that the association of these microRNAs with cognitive scores  
479 was stronger in the older age group ( $\geq 54$  years; **Figure 3B**). Additionally, a significant sex  
480 interaction was observed for the association of miR-192-5p and miR-215-5p (lightcyan  
481 module) with multiple cognitive domains, miR-4732-3p with executive function and miR-  
482 340-5p with crystallized intelligence. Sex-stratified analysis showed that these microRNAs  
483 were more strongly associated with most cognitive domains in men. The effect modification  
484 was especially pronounced for miR-215-5p. Higher expression of this microRNA was  
485 associated with worse working memory and crystallized intelligence performance in the total  
486 sample and among men, but with better performance in these domains among women  
487 (**Figure 3C**).

488 Seven microRNAs, including the abovementioned miR-215-5p, were inconsistently  
489 associated with cognition in our study and in previous studies by Comfort et al. and Yaqub et  
490 al. [12,13] (Section 3.2.1). As these previous studies included older participants compared to  
491 ours, the inconsistent associations of microRNAs with cognition might have been driven by  
492 age-dependent effects. Age-stratified analysis for these microRNAs partially confirmed this  
493 assumption. Specifically, for four microRNAs (miR-342-5p, miR-320b, miR-320c, miR-574-  
494 5p), the inconsistent association with cognition was stronger in younger participants and  
495 tended towards the null in older participants (**Supplementary Fig. S5A**). Similarly, the study  
496 by Comfort et al. included only male participants. For four of the microRNAs identified in  
497 this study (miR-342-5p, miR-320b, miR-320c, miR-30e-3p) the inconsistent association with  
498 cognition was stronger in women and tended towards the null in men (**Supplementary Fig.**  
499 **S5B**). However, the assumption of sex driving the inconsistent association with cognition was  
500 not confirmed for miR-215-5p. As mentioned above, higher miR-215-5p expression was  
501 associated with much worse cognitive function among men in our study, but with better  
502 cognitive function among the male population of Comfort et al.

### 503 3.3 Association of cognition-related microRNAs with brain MRI measures

504 Next, we assessed whether the expression of the 15 microRNAs identified as associated with  
505 cognition was also associated with mean cortical thickness, hippocampal volume, and total  
506 brain volume. Higher expression of miR-128-3p, miR-215-5p and miR-192-5p was  
507 significantly associated with a thinner cortex, and higher miR-192-5p expression was  
508 additionally associated with smaller total brain volume. On the contrary, higher expression of  
509 miR-4732-3p, miR-92b-3p, miR-1976 and miR-10401-3p was associated with a thicker  
510 cortex. Moreover, higher miR-125b-5p expression was associated with larger left  
511 hippocampal volume, which was consistent with its association with better cognitive  
512 function. Surprisingly, although miR-340-5p expression was associated with worse cognitive  
513 function, it was also associated with larger left hippocampal volume and, at borderline  
514 significance, a thinner cortex (**Figure 3A**).

515 ROI-specific analysis showed that the association of microRNAs with cortical thickness was  
516 overall strongest in the left hemisphere, and followed similar patterns for microRNAs in the  
517 same module. Specifically, the associations were strongest in the left middle temporal and  
518 postcentral gyri for lightcyan module microRNAs (miR-215-5p, miR-192-5p), and in the left  
519 precentral and superior temporal gyri for turquoise model microRNAs (miR-10401-3p, miR-  
520 1976, miR-92b-3p). For miR-4732-3p (salmon module), the associations were strongest  
521 bilaterally in the precentral and superior temporal regions, and in the right paracentral region.  
522 The association of miR-128-3p (purple module) with cortical thickness was overall weaker,  
523 and localized in the right middle and inferior temporal regions (**Figure 4**).

524 Lastly, it is worth mentioning that expression of miR-1976, miR-92b-3p, miR-128-3p and  
525 miR-192-5p was significantly or borderline significantly associated with the thickness of the  
526 entorhinal cortex.



### 527 **3.4 MicroRNA expression in tissues**

528 Using microRNATissueAtlas data, we determined that the majority of the 15 cognition-  
529 related microRNAs were expressed most abundantly across brain areas, such as the  
530 hippocampus, medulla oblongata, cerebellum, and cortex. MicroRNAs from the lightcyan  
531 module were the only exception to this, as they were expressed most abundantly in  
532 gastrointestinal tract tissues. The localization of miR-92b-3p and miR-128-3p in the cortex,  
533 hinted by their association with cortical thickness, was further reinforced by the high  
534 expression of these microRNA in the frontal lobe. Similarly, miR-125b-5p, which was  
535 associated with hippocampal volume, was also highly expressed in the hippocampus (**Figure**  
536 **5**).

### 537 **3.5 Functional genomics analysis**

#### 538 *3.5.1 Identification of microRNA target genes*

539 To better understand the function of the cognition-related microRNAs, we leveraged gene  
540 expression data, available in a subset of our study participants. In total, the 15 cognition-  
541 related microRNAs had 9072 putative target genes, and for 2560 of them expression of the  
542 targeting microRNA was negatively associated with gene expression. The close biological  
543 relation between miR-92a-3p and miR-92b-3p was corroborated by their relatively high  
544 number of shared negatively associated target genes (n=382 genes). Notably, these two  
545 microRNAs also shared a high number of negatively associated target genes with miR-128-  
546 3p (n=97). Beyond that, the 15 microRNAs had relatively few shared target genes  
547 (**Supplementary Fig. S6**).

#### 548 *3.5.2 Pathway enrichment analysis of microRNA target genes*

549 We then performed a Gene Ontology functional enrichment analysis of the negatively  
550 associated target genes per WGCNA module. This highlighted the distinct biological  
551 functions performed by each module. For example, the greenyellow module was highly  
552 enriched for “mitochondrial membrane permeability” and “mitochondrial transport”, the  
553 lightcyan module was highly enriched for “Wnt signaling”, “cell growth” and “wound  
554 healing”, while the turquoise module was highly enriched for “brain development”. Notably,  
555 pathways highly relevant to cognition were jointly enriched for several modules. This  
556 included “axon guidance”, “dendrite development”, “neurogenesis” and “synapse assembly”  
557 for the turquoise, purple, lightcyan and blue modules. Similarly, “transforming growth factor  
558 beta (TGF- $\beta$ ) signaling” was among the top results for the turquoise, brown, purple, lightcyan  
559 and blue modules, while “memory” was enriched for the turquoise, purple, greenyellow and  
560 blue modules. Moreover, “response to estradiol” was enriched for the lightcyan module  
561 **(Figure 6A)**.

### 562 *3.5.3 MicroRNA target genes in relation to general cognitive function*

563 To further validate the involvement of the 15 identified microRNAs in cognition, we tested  
564 the overlap between microRNA target genes and genes identified by a recent GWAS of  
565 general cognitive function. Notably, only targets of miR-92b-3p and miR-92a-3p were  
566 significantly overrepresented among the genes identified by the GWAS **(Figure 6B)**.

567

## 568 4 DISCUSSION

569 In the present study, we identified 15 microRNAs associated with cognitive domains in a  
570 large, general population-based cohort with a wide age range. Importantly, five of these  
571 microRNAs were identified by reproducing the results of previous studies. Our subsequent  
572 analyses using brain imaging and gene expression data enabled a detailed characterization of  
573 identified microRNAs, providing information on the mechanisms underlying their relation to  
574 cognition. Some microRNAs were associated with cortical thickness and hippocampal  
575 volume, while most were highly expressed in brain tissues and regulated key neuronal  
576 processes. Taken together, our large sample size, inclusion of previous studies, and analysis  
577 of multimodal data increase the robustness of our findings. Additionally, our results  
578 demonstrate the potential of identified microRNAs as biomarkers or therapeutic targets  
579 against cognitive dysfunction.

580 MicroRNAs associated with different cognitive domains or cortical regions could be  
581 investigated as blood-based biomarkers for disorders that preferentially affect these domains  
582 or regions, such as AD for memory and the temporal lobe, or Frontotemporal Dementia for  
583 executive function and the frontal lobe [38]. For example, miR-128-3p, which was  
584 upregulated in MCI patients in a past meta-analysis, was also associated with worse cognition  
585 in our study. In addition to MCI, miR-128-3p has also been dysregulated in AD [17], while  
586 suppressing its expression has been found to protect against AD pathology and memory loss  
587 in mice [39]. Moreover, we showed that it was associated with thickness in the temporal lobe  
588 and entorhinal cortex, which are affected very early in the pathophysiology of AD [40]. Early  
589 upregulation of this microRNA could indicate accelerated neurodegeneration, leading to  
590 brain atrophy and cognitive dysfunction. This would make it an ideal target for detecting and  
591 preventing AD-related cognitive dysfunction. However, contrary to the findings of our and

592 other studies, a previous population-based study found that miR-128-3p was downregulated  
593 in participants with worse cognition [15]. Thus, further investigations are needed to  
594 determine its exact association with cognition.

595 Several of the identified microRNAs were associated with cortical thickness in regions  
596 involved in various cognitive processes. This corroborates the importance of these  
597 microRNAs for cognition and could indicate that their relation with cognition is mediated by  
598 the modulation of brain structure. For example, we determined that microRNAs were  
599 strongly associated with cortical thickness in the precentral, superior temporal (miR-10401-  
600 3p, miR-1976, miR-92b-3p, miR-4732-3p), postcentral, and middle temporal regions (miR-  
601 215-5p, miR-192-5p, miR-128-3p). The superior and middle temporal regions are implicated  
602 in a host of cognitive tasks, including audiovisual processing and integration [41], declarative  
603 memory, and language [42]. The localization in the left postcentral and precentral gyri  
604 (primary motor and somatosensory cortex) might implicate these microRNAs in normal, non-  
605 neurodegenerative brain aging, as age-related atrophy is increased in these areas [27].  
606 Moreover, recent evidence supports the involvement of the sensorimotor region in higher  
607 cognitive functions, such as attention and learning for the primary motor cortex [43], or  
608 associative episodic memory for the somatosensory cortex [44]. Lastly, miR-340-5p and  
609 miR-125b-5p were associated with the volume of the hippocampus, perhaps the most  
610 established region in relation to memory and AD [45].

611 Our functional genomics analysis determined that most of the 15 microRNAs jointly regulate  
612 processes intrinsically related to cognition, such as memory, axon guidance, dendrite  
613 development, neurogenesis and synapse assembly. In addition, microRNAs from five  
614 modules jointly regulated TGF- $\beta$  signaling, which plays an important role in neuronal  
615 development and neuroprotection in neurodegeneration [46,47]. Of note, this included miR-

616 192-5p, which has been found to directly affect cognitive function through the modulation of  
617 TGF- $\beta$  signaling in a mouse model of depression [48]. Despite this overlap in enrichment  
618 results, the microRNAs in each module shared few common target genes, suggesting that  
619 they are involved in different, complementary stages of the abovementioned processes. These  
620 findings point towards possible interventions for the prevention or treatment of cognitive  
621 dysfunction. For example, miR-192-5p and miR-215-5p were associated with temporal lobe  
622 thickness and episodic verbal memory. The target genes of these microRNAs were related to  
623 WNT signaling, especially known for its involvement in synaptic plasticity and AD  
624 pathology [49]. This interaction with WNT signaling, which for miR-192-5p has also been  
625 observed experimentally [50], could be further investigated as a means of preventing cortical  
626 atrophy and cognitive dysfunction in aging or AD. Besides microRNA-regulated pathways,  
627 the functional genomics analysis particularly highlighted the importance of the closely related  
628 miR-92a-3p and miR-92b-3p. A significant proportion of the target genes of these  
629 microRNAs have been linked to cognition in a previous GWAS [36]. Moreover, miR-92b-3p  
630 was associated with cortical thickness and was highly expressed in the cortex and  
631 hippocampus. Importantly, both microRNAs have been previously shown to exert  
632 neuroprotective effects [51–54].

633 Due to the nature of our data and analysis, we cannot conclude causality of the observed  
634 associations. However, some of the identified microRNAs have been causally linked to  
635 cognition or brain health in past experimental studies. Among them, miR-134-5p has been  
636 most extensively studied as a regulator of synaptic plasticity, dendritogenesis, long-term  
637 potentiation, and neuronal injury [55–59]. Aberrant regulation of these processes by miR-  
638 134-5p can lead to cognitive deficits [57,60,61]. Similarly, miR-409-3p has been found to  
639 induce cognitive deficits through impairment of neuronal viability [62], while miR-192-5p  
640 mediates the effects on cognitive function of exercise [63] and, as mentioned above,

641 depression through TFG- $\beta$  [48]. Moreover, miR-340-5p has been found to exert  
642 neuroprotective effects [64], while miR-493-3p, miR-1976 and miR-125b-5p worsen the  
643 neurotoxic effects of stroke [65], Parkinson's disease [66], and AD [67].

644 Some of our findings were unexpected and suggest novel research questions regarding the  
645 relation of microRNAs with brain function. We identified seven microRNAs that were  
646 associated with cognition in opposite directions in our data compared to two previous studies  
647 [12,13]. We showed that this could be due to the differences in the examined populations.  
648 Specifically, for five out of seven microRNAs, the inconsistent association with cognition  
649 largely disappeared in subsets of our population that matched the age and sex composition of  
650 the previous studies. However, these inconsistent results illustrate that further validation is  
651 needed to determine the precise relation of these microRNAs with cognition. Moreover, three  
652 microRNAs (miR-128-3p, miR-92a-3p, miR-125b-5p) showed a stronger association with  
653 cognition in older participants. This could be attributed to their interaction with mechanisms  
654 of aging or neurodegeneration. For example, all three microRNAs have been implicated in  
655 AD pathogenesis [39,68,69]. Similarly, four microRNAs (miR-215-5p, miR-192-5p, miR-  
656 4732-3p, miR-340-5p) were associated with cognitive domain scores in a sex-dependent  
657 manner. This could be explained by an interaction of these microRNAs with sex hormone  
658 signaling, which is known to impact cognition [70]. In support of this, our functional  
659 enrichment results showed that miR-215-5p and miR-192-5p might regulate cellular  
660 responses to estradiol. For miR-192-5p, an interaction with estrogen receptors has also been  
661 observed experimentally [71]. However, further research is needed to define the mechanisms  
662 behind these age- and sex-dependent effects. Lastly, we observed an unexpected association  
663 of increased miR-340-5p expression with worse executive function and lower mean cortical  
664 thickness, but higher hippocampal volume. The consensus of past experimental studies  
665 supports the association of miR-340-5p with hippocampal volume, as it has been shown to

666 have neuroprotective effects [64,72,73]. These conflicting findings could imply that this  
667 microRNA might have pleiotropic, location-dependent functions. Thus, its action might be  
668 neuroprotective in the hippocampus, but neurotoxic in the cortex, resulting in a net negative  
669 association with cognition. However, further investigation is required to test this assumption.

670 Our study has both strengths and limitations. As mentioned, our large sample size, wide age  
671 range, and inclusion of previous similar studies increase the reliability of our findings.

672 Moreover, we were able to comprehensively characterize microRNAs of interest and draw  
673 conclusions as to their function, by combining an extensive neuropsychological test battery,  
674 individual-level gene expression data, detailed brain imaging measures and publicly available  
675 resources. However, our study is not without drawbacks. Our use of WGCNA is based on the  
676 assumption that similarly expressed microRNAs have shared biological functions, a principle  
677 that has been previously contested [74]. Furthermore, as is common in population-based  
678 studies, our study participants were all residents of the same geographical region, limiting the  
679 generalizability of our findings. Lastly, when comparing our results to previous similar  
680 studies, there was a relatively small overlap and even some conflicting findings. This  
681 illustrates the necessity for the validation of study results and for the standardization of  
682 microRNA sampling and measurement methods.

683 In conclusion, here we identified a signature of five previously identified and 10 novel  
684 microRNAs associated with cognitive function across different domains. Some of these  
685 microRNAs were concurrently related to cortical thickness and hippocampal volume,  
686 suggesting that they regulate cognitive processes through modulation of brain structure. Our  
687 functional genomics analysis demonstrated the importance of the identified microRNAs for a  
688 number of neuronal functions and emphasized miR-92a-3p and miR-92b-3p, which were  
689 abundant in cortical tissue and regulated cognition-related genes. In the future, the identified

690 microRNAs could be leveraged to develop signatures for the early detection of dementia in  
691 clinical or research settings. Moreover, future interventional studies could utilize them for the  
692 prevention of cognitive dysfunction due to aging or neurodegeneration.

693

#### 694 **Abbreviations**

695 AD, Alzheimer’s Disease; ROIs, Regions Of Interest; eTIV, estimated Total Intracranial  
696 Volume; DKT, Desikan–Killiany–Tourville; SD, Standard Deviation; WGCNA, Weighted  
697 Gene Co-Expression Analysis; fdr, false discovery rate; GWAS, Genome-Wide Association  
698 Study; MCI, Mild Cognitive Impairment; CI, Confidence Interval; HCV, Hippocampal  
699 Volume; TGF- $\beta$ , transforming growth factor beta

700

701



702 **Acknowledgements**

703 We wish to thank all participants of the Rhineland Study and the study personnel that was  
704 involved in data collection. Additionally, we would like to thank Dr. Dan Liu for her  
705 feedback on a previous version of this manuscript.

706 **Sources of Funding**

707 This work was further supported by the Federal Ministry of Education and Research grant  
708 [FKZ: 01KX2230] with the title "PreBeDem - Mit Prävention und Behandlung gegen  
709 Demenz" and the Helmholtz Association under the 2023 Innovation Pool. The Rhineland  
710 Study is funded by the German Center for Neurodegenerative Diseases (DZNE). Andre  
711 Fischer received funding from the DFG priority program 1738, SFB1286, SFB 1002, by  
712 Germany's Excellence Strategy - EXC 2067/1 390729940, the ERA-Net Neuron project  
713 EPINEURODEVO and the JPND project EPI-3E.

714

715 **References**

- 716 [1] Chowdhary N, Barbui C, Anstey KJ, Kivipelto M, Barbera M, Peters R, et al.  
717 Reducing the risk of cognitive decline and dementia: WHO recommendations. *Front*  
718 *Neurol* 2021;12:765584. <https://doi.org/10.3389/fneur.2021.765584>.
- 719 [2] Morley JE, Morris JC, Berg-Weger M, Borson S, Carpenter BD, Del Campo N, et al.  
720 Brain health: the importance of recognizing cognitive impairment: an IAGG  
721 consensus conference. *J Am Med Dir Assoc* 2015;16:731–9.  
722 <https://doi.org/10.1016/j.jamda.2015.06.017>.
- 723 [3] Howieson D. Current limitations of neuropsychological tests and assessment  
724 procedures. *Clin Neuropsychol* 2019;33:200–8.  
725 <https://doi.org/10.1080/13854046.2018.1552762>.
- 726 [4] Whelan R, Barbey FM, Cominetti MR, Gillan CM, Rosická AM. Developments in  
727 scalable strategies for detecting early markers of cognitive decline. *Transl Psychiatry*  
728 2022;12:473. <https://doi.org/10.1038/s41398-022-02237-w>.
- 729 [5] Fiocco AJ, Krieger L, D’Amico D, Parrott MD, Laurin D, Gaudreau P, et al. A  
730 systematic review of existing peripheral biomarkers of cognitive aging: Is there  
731 enough evidence for biomarker proxies in behavioral modification interventions?: An  
732 initiative in association with the nutrition, exercise and lifestyle team of the Canadian  
733 Consortium on Neurodegeneration in Aging. *Ageing Res Rev* 2019;52:72–119.  
734 <https://doi.org/10.1016/j.arr.2019.04.008>.
- 735 [6] Mehta K, Mohebvi M, Pasco JA, Williams LJ, Sui SX, Walder K, et al. A plasma  
736 protein signature associated with cognitive function in men without severe cognitive

- 737 impairment. *Alzheimers Res Ther* 2023;15:148. [https://doi.org/10.1186/s13195-023-](https://doi.org/10.1186/s13195-023-01294-7)  
738 01294-7.
- 739 [7] Salta E, De Strooper B. Non-coding RNAs with essential roles in neurodegenerative  
740 disorders. *Lancet Neurol* 2012;11:189–200. [https://doi.org/10.1016/S1474-](https://doi.org/10.1016/S1474-4422(11)70286-1)  
741 4422(11)70286-1.
- 742 [8] Woldemichael BT, Mansuy IM. Micro-RNAs in cognition and cognitive disorders:  
743 Potential for novel biomarkers and therapeutics. *Biochem Pharmacol* 2016;104:1–7.  
744 <https://doi.org/10.1016/j.bcp.2015.11.021>.
- 745 [9] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*  
746 2004;116:281–97. [https://doi.org/10.1016/s0092-8674\(04\)00045-5](https://doi.org/10.1016/s0092-8674(04)00045-5).
- 747 [10] Juźwik CA, S Drake S, Zhang Y, Paradis-Isler N, Sylvester A, Amar-Zifkin A, et al.  
748 microRNA dysregulation in neurodegenerative diseases: A systematic review. *Prog*  
749 *Neurobiol* 2019;182:101664. <https://doi.org/10.1016/j.pneurobio.2019.101664>.
- 750 [11] Walgrave H, Zhou L, De Strooper B, Salta E. The promise of microRNA-based  
751 therapies in Alzheimer’s disease: challenges and perspectives. *Mol Neurodegener*  
752 2021;16:76. <https://doi.org/10.1186/s13024-021-00496-7>.
- 753 [12] Yaqub A, Mens MMJ, Klap JM, Weverling GJ, Klatser P, Brakenhoff JPJ, et al.  
754 Genome-wide profiling of circulatory microRNAs associated with cognition and  
755 dementia. *Alzheimers Dement* 2022. <https://doi.org/10.1002/alz.12752>.
- 756 [13] Comfort N, Wu H, De Hoff P, Vuppala A, Vokonas PS, Spiro A, et al. Extracellular  
757 microRNA and cognitive function in a prospective cohort of older men: The Veterans

- 758 Affairs Normative Aging Study. *Aging (Albany NY)* 2022;14:6859–86.  
759 <https://doi.org/10.18632/aging.204268>.
- 760 [14] Van der Auwera S, Garvert L, Ameling S, Völzke H, Nauck M, Völker U, et al. The  
761 interplay between micro RNAs and genetic liability to Alzheimer’s Disease on  
762 memory trajectories in the general population. *Psychiatry Res* 2023;323:115141.  
763 <https://doi.org/10.1016/j.psychres.2023.115141>.
- 764 [15] Sadlon A, Takousis P, Evangelou E, Prokopenko I, Alexopoulos P, Udeh-Momoh  
765 CM, et al. Association of Blood MicroRNA Expression and Polymorphisms with  
766 Cognitive and Biomarker Changes in Older Adults. *J Prev Alzheimers Dis*  
767 2024;11:230–40. <https://doi.org/10.14283/jpad.2023.99>.
- 768 [16] Islam MR, Kaurani L, Berulava T, Heilbronner U, Budde M, Centeno TP, et al. A  
769 microRNA signature that correlates with cognition and is a target against cognitive  
770 decline. *EMBO Mol Med* 2021;13:e13659.  
771 <https://doi.org/10.15252/emmm.202013659>.
- 772 [17] Yoon S, Kim SE, Ko Y, Jeong GH, Lee KH, Lee J, et al. Differential expression of  
773 MicroRNAs in Alzheimer’s disease: a systematic review and meta-analysis. *Mol*  
774 *Psychiatry* 2022;27:2405–13. <https://doi.org/10.1038/s41380-022-01476-z>.
- 775 [18] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion  
776 for RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.  
777 <https://doi.org/10.1186/s13059-014-0550-8>.

- 778 [19] Coors A, Breteler MMB, Ettinger U. Processing speed, but not working memory or  
779 global cognition, is associated with pupil diameter during fixation. *Psychophysiology*  
780 2022;59:e14089. <https://doi.org/10.1111/psyp.14089>.
- 781 [20] Mueller ST, Piper BJ. The psychology experiment building language (PEBL) and  
782 PEBL test battery. *J Neurosci Methods* 2014;222:250–9.  
783 <https://doi.org/10.1016/j.jneumeth.2013.10.024>.
- 784 [21] Boenniger MM, Staerk C, Coors A, Huijbers W, Ettinger U, Breteler MMB. Ten  
785 German versions of Rey’s auditory verbal learning test: Age and sex effects in 4,000  
786 adults of the Rhineland Study. *J Clin Exp Neuropsychol* 2021;43:637–53.  
787 <https://doi.org/10.1080/13803395.2021.1984398>.
- 788 [22] Coors A, Merten N, Ward DD, Schmid M, Breteler MMB, Ettinger U. Strong age but  
789 weak sex effects in eye movement performance in the general adult population:  
790 Evidence from the Rhineland Study. *Vision Res* 2021;178:124–33.  
791 <https://doi.org/10.1016/j.visres.2020.10.004>.
- 792 [23] Lehr S. Mehrfachwahl-Wortschatz-Intelligenztest: MWT-B . Spitta GmbH; 2005.
- 793 [24] Lohner V, Enkirch SJ, Hattingen E, Stöcker T, Breteler MMB. Safety of Tattoos,  
794 Permanent Make-Up, and Medical Implants in Population-Based 3T Magnetic  
795 Resonance Brain Imaging: The Rhineland Study. *Front Neurol* 2022;13:795573.  
796 <https://doi.org/10.3389/fneur.2022.795573>.
- 797 [25] van der Kouwe AJW, Benner T, Salat DH, Fischl B. Brain morphometry with  
798 multiecho MPRAGE. *Neuroimage* 2008;40:559–69.  
799 <https://doi.org/10.1016/j.neuroimage.2007.12.025>.

- 800 [26] Fischl B. FreeSurfer. *Neuroimage* 2012;62:774–81.  
801 <https://doi.org/10.1016/j.neuroimage.2012.01.021>.
- 802 [27] Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavedo E, et al. Brain atrophy  
803 in Alzheimer’s Disease and aging. *Ageing Res Rev* 2016;30:25–48.  
804 <https://doi.org/10.1016/j.arr.2016.01.002>.
- 805 [28] Klein A, Tourville J. 101 labeled brain images and a consistent human cortical  
806 labeling protocol. *Front Neurosci* 2012;6:171.  
807 <https://doi.org/10.3389/fnins.2012.00171>.
- 808 [29] Wolfe CJ, Kohane IS, Butte AJ. Systematic survey reveals general applicability of  
809 “guilt-by-association” within gene coexpression networks. *BMC Bioinformatics*  
810 2005;6:227. <https://doi.org/10.1186/1471-2105-6-227>.
- 811 [30] Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network  
812 analysis. *BMC Bioinformatics* 2008;9:559. <https://doi.org/10.1186/1471-2105-9-559>.
- 813 [31] Langfelder P, Horvath S. Fast R functions for robust correlations and hierarchical  
814 clustering. *J Stat Softw* 2012;46. <https://doi.org/10.18637/jss.v046.i11>.
- 815 [32] Keller A, Gröger L, Tschernig T, Solomon J, Laham O, Schaum N, et al.  
816 miRNATissueAtlas2: an update to the human miRNA tissue atlas. *Nucleic Acids Res*  
817 2022;50:D211–21. <https://doi.org/10.1093/nar/gkab808>.
- 818 [33] Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, et al. The  
819 multiMiR R package and database: integration of microRNA-target interactions along  
820 with their disease and drug associations. *Nucleic Acids Res* 2014;42:e133.  
821 <https://doi.org/10.1093/nar/gku631>.

- 822 [34] Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal  
823 enrichment tool for interpreting omics data. *Innovation (Camb)* 2021;2:100141.  
824 <https://doi.org/10.1016/j.xinn.2021.100141>.
- 825 [35] Sayols S. rrvgo: a Bioconductor package to reduce and visualize Gene Ontology  
826 terms. *Bioconductor*; 2020.
- 827 [36] Davies G, Lam M, Harris SE, Trampush JW, Luciano M, Hill WD, et al. Study of  
828 300,486 individuals identifies 148 independent genetic loci influencing general  
829 cognitive function. *Nat Commun* 2018;9:2098. [https://doi.org/10.1038/s41467-018-](https://doi.org/10.1038/s41467-018-04362-x)  
830 [04362-x](https://doi.org/10.1038/s41467-018-04362-x).
- 831 [37] Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences  
832 to function. *Nucleic Acids Res* 2019;47:D155–62.  
833 <https://doi.org/10.1093/nar/gky1141>.
- 834 [38] Trojsi F, Christidi F, Migliaccio R, Santamaría-García H, Santangelo G. Behavioural  
835 and cognitive changes in neurodegenerative diseases and brain injury. *Behav Neurol*  
836 2018;2018:4935915. <https://doi.org/10.1155/2018/4935915>.
- 837 [39] Liu Y, Zhang Y, Liu P, Bai H, Li X, Xiao J, et al. MicroRNA-128 knockout inhibits  
838 the development of Alzheimer’s disease by targeting PPAR $\gamma$  in mouse models. *Eur J*  
839 *Pharmacol* 2019;843:134–44. <https://doi.org/10.1016/j.ejphar.2018.11.004>.
- 840 [40] Chandra A, Dervenoulas G, Politis M, Alzheimer’s Disease Neuroimaging Initiative.  
841 Magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment. *J*  
842 *Neurol* 2019;266:1293–302. <https://doi.org/10.1007/s00415-018-9016-3>.



- 843 [41] Hein G, Knight RT. Superior temporal sulcus--It's my area: or is it? *J Cogn Neurosci*  
844 2008;20:2125–36. <https://doi.org/10.1162/jocn.2008.20148>.
- 845 [42] Roger E, Banjac S, Thiebaut de Schotten M, Baciú M. Missing links: The functional  
846 unification of language and memory (LUM). *Neurosci Biobehav Rev*  
847 2022;133:104489. <https://doi.org/10.1016/j.neubiorev.2021.12.012>.
- 848 [43] Bhattacharjee S, Kashyap R, Abualait T, Annabel Chen S-H, Yoo W-K, Bashir S.  
849 The role of primary motor cortex: more than movement execution. *J Mot Behav*  
850 2021;53:258–74. <https://doi.org/10.1080/00222895.2020.1738992>.
- 851 [44] Summerfield C, Greene M, Wager T, Egnér T, Hirsch J, Mangels J. Neocortical  
852 connectivity during episodic memory formation. *PLoS Biol* 2006;4:e128.  
853 <https://doi.org/10.1371/journal.pbio.0040128>.
- 854 [45] Petersen RC, Jack CR, Xu YC, Waring SC, O'Brien PC, Smith GE, et al. Memory  
855 and MRI-based hippocampal volumes in aging and AD. *Neurology* 2000;54:581–7.  
856 <https://doi.org/10.1212/wnl.54.3.581>.
- 857 [46] Meyers EA, Kessler JA. TGF- $\beta$  Family Signaling in Neural and Neuronal  
858 Differentiation, Development, and Function. *Cold Spring Harb Perspect Biol* 2017;9.  
859 <https://doi.org/10.1101/cshperspect.a022244>.
- 860 [47] Dobolyi A, Vincze C, Pál G, Lovas G. The neuroprotective functions of transforming  
861 growth factor beta proteins. *Int J Mol Sci* 2012;13:8219–58.  
862 <https://doi.org/10.3390/ijms13078219>.
- 863 [48] Tang C-Z, Yang J-T, Liu Q-H, Wang Y-R, Wang W-S. Up-regulated miR-192-5p  
864 expression rescues cognitive impairment and restores neural function in mice with

- 865 depression via the Fbln2-mediated TGF- $\beta$ 1 signaling pathway. *FASEB J*  
866 2019;33:606–18. <https://doi.org/10.1096/fj.201800210RR>.
- 867 [49] Palomer E, Buechler J, Salinas PC. Wnt signaling deregulation in the aging and  
868 alzheimer's brain. *Front Cell Neurosci* 2019;13:227.  
869 <https://doi.org/10.3389/fncel.2019.00227>.
- 870 [50] Pan Y, Sun Y, Liu Z, Zhang C. miR-192-5p upregulation mediates the suppression of  
871 curcumin in human NSCLC cell proliferation, migration and invasion by targeting  
872 c-Myc and inactivating the Wnt/ $\beta$ -catenin signaling pathway. *Mol Med Report*  
873 2020;22:1594–604. <https://doi.org/10.3892/mmr.2020.11213>.
- 874 [51] Winkler I, Engler JB, Vieira V, Bauer S, Liu Y-H, Di Liberto G, et al. MicroRNA-  
875 92a-CPEB3 axis protects neurons against inflammatory neurodegeneration. *Sci Adv*  
876 2023;9:eadi6855. <https://doi.org/10.1126/sciadv.adi6855>.
- 877 [52] Liu E, Sun H, Wu J, Kuang Y. MiR-92b-3p regulates oxygen and glucose  
878 deprivation-reperfusion-mediated apoptosis and inflammation by targeting TRAF3 in  
879 PC12 cells. *Exp Physiol* 2020;105:1792–801. <https://doi.org/10.1113/EP088708>.
- 880 [53] Shen J, Li G, Zhu Y, Xu Q, Zhou H, Xu K, et al. Foxo1-induced miR-92b down-  
881 regulation promotes blood-brain barrier damage after ischaemic stroke by targeting  
882 NOX4. *J Cell Mol Med* 2021;25:5269–82. <https://doi.org/10.1111/jcmm.16537>.
- 883 [54] Hu Z-Y, Yang Z-B, Zhang R, Luo X-J, Peng J. The Protective Effect of Vitexin  
884 Compound B-1 on Rat Cerebral I/R Injury through a Mechanism Involving  
885 Modulation of miR-92b/NOX4 Pathway. *CNS Neurol Disord Drug Targets*  
886 2023;22:137–47. <https://doi.org/10.2174/1871527321666220324115848>.

- 887 [55] Wang G, An T, Lei C, Zhu X, Yang L, Zhang L, et al. Antidepressant-like effect of  
888 ginsenoside Rb1 on potentiating synaptic plasticity via the miR-134-mediated BDNF  
889 signaling pathway in a mouse model of chronic stress-induced depression. *J Ginseng*  
890 *Res* 2022;46:376–86. <https://doi.org/10.1016/j.jgr.2021.03.005>.
- 891 [56] Wang G, Liu Y, Zhu X, Lin K, Li M, Wu Z, et al. Knockdown of miRNA-134-5p  
892 rescues dendritic deficits by promoting AMPK-mediated mitophagy in a mouse model  
893 of depression. *Neuropharmacology* 2022;214:109154.  
894 <https://doi.org/10.1016/j.neuropharm.2022.109154>.
- 895 [57] Bicker S, Lackinger M, Weiß K, Schratt G. MicroRNA-132, -134, and -138: a  
896 microRNA troika rules in neuronal dendrites. *Cell Mol Life Sci* 2014;71:3987–4005.  
897 <https://doi.org/10.1007/s00018-014-1671-7>.
- 898 [58] Baby N, Alagappan N, Dheen ST, Sajikumar S. MicroRNA-134-5p inhibition rescues  
899 long-term plasticity and synaptic tagging/capture in an A $\beta$ (1-42)-induced model of  
900 Alzheimer's disease. *Aging Cell* 2020;19:e13046. <https://doi.org/10.1111/acer.13046>.
- 901 [59] Wang C, Zhang H, Li J. LncRNA JHDM1D-AS1 Suppresses MPP<sup>+</sup>-Induced  
902 Neuronal Injury in Parkinson's Disease via miR-134-5p/PIK3R3 Axis. *Neurotox Res*  
903 2021;39:1771–81. <https://doi.org/10.1007/s12640-021-00437-8>.
- 904 [60] Shen J, Xu L, Qu C, Sun H, Zhang J. Resveratrol prevents cognitive deficits induced  
905 by chronic unpredictable mild stress: Sirt1/miR-134 signalling pathway regulates  
906 CREB/BDNF expression in hippocampus in vivo and in vitro. *Behav Brain Res*  
907 2018;349:1–7. <https://doi.org/10.1016/j.bbr.2018.04.050>.

- 908 [61] Liu X, Zhang R, Wu Z, Si W, Ren Z, Zhang S, et al. miR-134-5p/Foxp2/Syn1 is  
909 involved in cognitive impairment in an early vascular dementia rat model. *Int J Mol*  
910 *Med* 2019;44:1729–40. <https://doi.org/10.3892/ijmm.2019.4331>.
- 911 [62] Wu T, Tang C, Fan J, Tao J. Administration of rTMS Alleviates Stroke-Induced  
912 Cognitive Deficits by Modulating miR-409-3p/CTRP3/AMPK/Sirt1 Axis. *J Mol*  
913 *Neurosci* 2022;72:507–15. <https://doi.org/10.1007/s12031-021-01924-5>.
- 914 [63] Qin Z, Han X, Ran J, Guo S, Lv L. Exercise-Mediated Alteration of miR-192-5p Is  
915 Associated with Cognitive Improvement in Alzheimer’s Disease.  
916 *Neuroimmunomodulation* 2022;29:36–43. <https://doi.org/10.1159/000516928>.
- 917 [64] He G, Ni H, Wang K, Gao H, Li Y, Gu J, et al. Dexmedetomidine attenuates the  
918 neuroinflammation and cognitive dysfunction in aged mice by targeting the  
919 SNHG14/miR-340/NF- $\kappa$ B axis. *Biomed Rep* 2023;19:100.  
920 <https://doi.org/10.3892/br.2023.1682>.
- 921 [65] Li Q, He Q, Baral S, Mao L, Li Y, Jin H, et al. MicroRNA-493 regulates  
922 angiogenesis in a rat model of ischemic stroke by targeting MIF. *FEBS J*  
923 2016;283:1720–33. <https://doi.org/10.1111/febs.13697>.
- 924 [66] Qiu F, Wu Y, Xie G, Cao H, Du M, Jiang H. MiRNA-1976 Regulates the Apoptosis  
925 of Dopaminergic Neurons by Targeting the PINK1 Gene. *J Integr Neurosci*  
926 2023;22:45. <https://doi.org/10.31083/j.jin2202045>.
- 927 [67] Banzhaf-Strathmann J, Benito E, May S, Arzberger T, Tahirovic S, Kretschmar H,  
928 et al. MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in

- 929 Alzheimer's disease. *EMBO J* 2014;33:1667–80.  
930 <https://doi.org/10.15252/emboj.201387576>.
- 931 [68] Li X, Wang Z, Tan L, Wang Y, Lu C, Chen R, et al. Correcting miR92a-vGAT-  
932 Mediated GABAergic Dysfunctions Rescues Human Tau-Induced Anxiety in Mice.  
933 *Mol Ther* 2017;25:140–52. <https://doi.org/10.1016/j.ymthe.2016.10.010>.
- 934 [69] Zhang L, Dong H, Si Y, Wu N, Cao H, Mei B, et al. miR-125b promotes tau  
935 phosphorylation by targeting the neural cell adhesion molecule in neuropathological  
936 progression. *Neurobiol Aging* 2019;73:41–9.  
937 <https://doi.org/10.1016/j.neurobiolaging.2018.09.011>.
- 938 [70] Itoh N, Itoh Y, Meyer CE, Suen TT, Cortez-Delgado D, Rivera Lomeli M, et al.  
939 Estrogen receptor beta in astrocytes modulates cognitive function in mid-age female  
940 mice. *Nat Commun* 2023;14:6044. <https://doi.org/10.1038/s41467-023-41723-7>.
- 941 [71] Kim YS, Park SJ, Lee YS, Kong HK, Park JH. miRNAs involved in LY6K and  
942 estrogen receptor  $\alpha$  contribute to tamoxifen-susceptibility in breast cancer. *Oncotarget*  
943 2016;7:42261–73. <https://doi.org/10.18632/oncotarget.9950>.
- 944 [72] Tu X, Zhang H, Chen S, Ding Y-H, Wu X, Liang R, et al. LncRNA CEBPA-AS1  
945 alleviates cerebral ischemia-reperfusion injury by sponging miR-340-5p regulating  
946 APPL1/LKB1/AMPK pathway. *FASEB J* 2022;36:e22075.  
947 <https://doi.org/10.1096/fj.202100826RR>.
- 948 [73] Tan X, Luo Y, Pi D, Xia L, Li Z, Tu Q. MiR-340 Reduces the Accumulation of  
949 Amyloid- $\beta$  Through Targeting BACE1 ( $\beta$ -site Amyloid Precursor Protein Cleaving

- 950 Enzyme 1) in Alzheimer’s Disease. *Curr Neurovasc Res* 2020;17:86–92.  
951 <https://doi.org/10.2174/1567202617666200117103931>.
- 952 [74] Gillis J, Pavlidis P. “Guilt by association” is the exception rather than the rule in gene  
953 networks. *PLoS Comput Biol* 2012;8:e1002444.  
954 <https://doi.org/10.1371/journal.pcbi.1002444>.
- 955 [75] Mowinckel AM, Vidal-Piñeiro D. Visualization of brain statistics with R packages  
956 *ggseg* and *ggseg3d*. *Advances in Methods and Practices in Psychological Science*  
957 2020;3:466–83. <https://doi.org/10.1177/2515245920928009>.

**Table 1:** Study participant characteristics

<b>Variable</b>	<b>Participants with complete cognitive examination and microRNA expression data, N = 2869 *</b>	<b>Participants with complete cognitive examination, microRNA expression, and brain MRI data, N = 2045 †, ‡</b>	<b>Participants with complete cognitive examination, microRNA expression, and gene expression data, N = 2138 ‡</b>
Age (years), mean (SD)	55.01(14.13)	54.31(13.90)	54.99 (14.18)
Sex, n (%)			
Female	1595 (56%)	1149 (56%)	1173 (55%)
Male	1274 (44%)	896 (44%)	965 (45%)
Global cognition (z-score), mean (SD) ¶	0.01 (0.64)	0.05 (0.62)	0.01 (0.63)
Executive function (z-score), mean (SD) ¶	-0.03 (0.75)	0.02 (0.73)	-0.02 (0.75)
Working memory (z-score), mean (SD) ¶	-0.01 (0.72)	0.03 (0.71)	0.00 (0.71)
Ep. verbal memory (z-score), mean (SD) ¶	0.06 (0.96)	0.11 (0.93)	0.04 (0.96)
Processing speed (z-score), mean (SD) ¶	0.02 (0.83)	0.06 (0.82)	0.03 (0.83)
Crystalized Intelligence (z-score), mean (SD) ¶	0.02 (0.96)	0.06 (0.93)	0.02 (0.96)
First language, n (%)			
German	2682 (94%)	1914 (94%)	2006 (94%)
Other	182 (6.4%)	130 (6.4%)	129 (6.0%)

Educational level, n (%)			
Low	55 (1.9%)	34 (1.7%)	34 (1.6%)
Middle	1248 (44%)	844 (42%)	928 (44%)
High	1543 (54%)	1152 (57%)	1155 (55%)
Left hippocampal volume (mm <sup>3</sup> ), mean (SD)	-	3.89×10 <sup>3</sup> (0.46×10 <sup>3</sup> )	3.88×10 <sup>3</sup> (0.46×10 <sup>3</sup> )
Right hippocampal volume (mm <sup>3</sup> ), mean (SD)	-	4.05 ×10 <sup>3</sup> (0.49×10 <sup>3</sup> )	4.04 ×10 <sup>3</sup> (0.49×10 <sup>3</sup> )
Total brain volume (mm <sup>3</sup> ), mean (SD)	-	1116.40×10 <sup>3</sup> (120.73×10 <sup>3</sup> )	1115.78×10 <sup>3</sup> (120.02×10 <sup>3</sup> )
eTIV(mm <sup>3</sup> ), mean (SD)	-	1.56×10 <sup>6</sup> (0.16×10 <sup>6</sup> )	1.56×10 <sup>6</sup> (0.16×10 <sup>6</sup> )
Mean cortical thickness (mm), mean (SD)	-	2.45 (0.09)	2.45 (0.09)

---


\* Participants with data additionally missing for crystallized intelligence: n=190

† Values have not been adjusted for head size. Participants with data additionally missing for individual imaging markers: cortical thickness: n=17; total brain volume: n=18; hippocampal volume: n=4

‡ Subset of participants with complete cognitive examination and microRNA expression data


¶ Cognitive examination z-scores were generated based on summary statistics from the first 5000 participants of the Rhineland Study.






**Figure 1: Replication of previous findings on microRNAs associated with cognition, AD or MCI.**

Replication of microRNAs that were identified as associated with cognition in previous cross-sectional population-based studies [12–16] (A), one previous longitudinal population-based study (B) [13], and a previous meta-analysis of microRNAs dysregulated in AD and MCI (C) [17]. Details on the studies included can be found in **Supplementary Table S1**. The sample sizes of included studies are in parentheses next to study names. Statistical significance is indicated by the asterisks. MicroRNAs that appeared in multiple included studies are marked with “+”. MicroRNAs are marked with “+” in parentheses when their higher expression was associated with better cognitive function in included studies, and with “-” in the opposite case. For the AD and MCI meta-analysis, “+” indicates higher expression of the microRNA in controls compared to patients. MicroRNAs that were significantly associated with cognition with a similar direction in the included studies and in our data have been annotated with blue color and are outlined with a blue box. Annotated with red color are microRNAs that were significantly associated with cognition in our study, but in an opposite direction compared to included studies. Abbreviations: AD, Alzheimer’s Disease; MCI, Mild Cognitive Impairment; SD, Standard Deviation




**Figure 2: Hypothesis-free association of microRNA and module expression with cognition.**

(A, B) Linear regression coefficients and significance levels for the association between co-expression modules and cognitive scores. Shown are Model 1 (A) which was adjusted for age and sex, and Model 2 (B) which was additionally adjusted for first (native) language and educational level. Modules are named after colors, and numbers in parentheses indicate the number of microRNAs within each module. Significance was determined after correcting for multiple comparisons with the *fdr* method. (C) Volcano plots of the *per microRNA* association of all microRNAs measured in our study with global cognition, executive function and episodic verbal memory scores. The *P* value shown in the y-axis has not been corrected for multiple testing. Top microRNAs for each score are annotated and co-expression modules are shown in parentheses. MicroRNAs that reached statistical significance for at least one phenotype, after multiple testing correction (*fdr* ≤ 0.05), are shown with triangles and have been marked with an asterisk (\*). Hub microRNAs are annotated with blue color. Abbreviations: *fdr*, false discovery rate; SD, Standard Deviation




**Figure 3:** Association of microRNA expression with cognitive scores and brain imaging measures. The heatmap (A) shows the association of microRNA expression with cognitive scores and brain imaging measures. Included were microRNAs identified as associated with cognition in our literature replication, *co-expression* and *per microRNA* analyses. The association of some microRNAs with cognitive domain scores was modified by sex and age. This is illustrated in (B) for sex and (C) for age, which show the standardized regression betas and 95% confidence intervals for the sex- and age-stratified association of these microRNAs with each cognitive score. Linear regression analyses were based on Model 1, which included as covariates age and sex, except for the sex-stratified analysis which was controlled only for age. Abbreviations: SD, Standard Deviation; fdr, false discovery rate; HCV, Hippocampal Volume; CI, Confidence Interval

## Association of microRNA expression with regional cortical thickness




**Figure 4: Region-specific association between microRNA expression and brain cortical thickness.** Regions of interest have been mapped based on the Desikan-Killiany cortical atlas. The color indicates the standardized  $\beta$  for the regions in which microRNA expression was significantly associated with cortical thickness. The analysis was performed only for microRNAs that were significantly associated with cognition and mean cortical thickness across both hemispheres. The visualization was created with the *ggseg* (v. 1.6.5) and *ggsegDKT* (v. 1.0.1.1) R packages [75].  
Abbreviations: SD, Standard Deviation

## MicroRNA expression in tissues



**Figure 5: Tissue expression analysis of cognition-related microRNAs**

Boxplots of tissue expression of microRNAs associated with cognition. Data was obtained from the microRNA Tissue Atlas [32], based on post-mortem samples taken from 6 human donors (here indicated by the colored dots). The module each microRNA belongs to is shown in parentheses. The top 5 tissues for each microRNA, based on median microRNA expression, are shown. Note that, to allow for better comparison of relative expression in tissues for each microRNA, the scale of the x-axis (expression z-score) varies.

**A****Most enriched pathways for microRNA target genes per co-expression module****B****Enrichment of microRNA target genes in GWAS of general cognitive function****Figure 6: Function genomics analysis of cognition-related microRNAs**

(A) Results of *Gene Ontology: Biological Processes* enrichment analysis of negatively associated target genes of the microRNAs in each co-expression module. The top 10 most enriched terms (based on  $P$  values) are shown. The numbers in parentheses indicate the number of target genes in each enriched term.  $P$  values have been corrected for multiple testing using the  $fdr$  method. Note that, to allow for better comparison of relative enrichment in each module, the scale of the x-axis (negative logarithm of  $fdr$ ) varies. (B) Overlap and overrepresentation (determined with a hypergeometric test) of negatively associated target genes of microRNA in a GWAS of global cognitive function [36].